All News
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
TICOPA Study: Tight Control in Psoriatic Arthritis
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
Read Article
Adalimumab FDA Approved for Hidradenitis Suppurativa
Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.
Read Article
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
Read Article
Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Read Article
Priorities for NIAMS Research Funding
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Read Article
Psoriasis Patients Satisfied with Biologics
A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy.
Read Article
International Psoriasis Council Publishes its Research Priorities
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Read Article
AstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Read Article
10 Year Study Identifies Predictors of Skin Progression in Systemic Sclerosis
The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.
Read Article
Bidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Read Article
Psoriasis and Psoriatic Arthritis Have an Increased Risk of Gout
The frequency of gout among patients with psoriatic disease was studied in two cohorts of 98,810 patients from the Health Professionals Follow-up Study (1986-2010) and the Nurses' Health Study (1998-2010).
Read ArticleWhat's Your Diagnosis? Truncal Rash, Arthritis and +ANA
An 80 year old woman complains of 3 months of rash on her back. It is modestly pruritic. The lesions are both annular and papular appearing over her back, torso and upper arms. She also complains of pain and swelling in her fingers.
Read Article
FUTURE 2 Trial Shows Secukinumab to be Effective in Psoriatic Arthritis
Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.
Read Article
Management of Digital Ulcers in Scleroderma
Currently there are no FDA-approved medications for the treatment of digital ulcerations in the United States. Digital ulcers are a common, unfortunate and difficult to manage consequence of the vascular obliteration and fibrosis that accompanies systemic sclerosis.
Read Article
Psoriatic Arthritis Occurs in 10-15% of Psoriasis Patients
Estimates on the prevalence of psoriatic arthritis among psoriasis patients has varied widely, ranging from 5-40%. A systematic review of the literature shows that prevalence of undiagnosed PsA was 15.5% when all studies were considered and 10.1% when only epidemiological studies were consi
Read Article
Tofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose
A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.
Read Article
Sildenafil May Help Heal Scleroderma Ulcers
A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.
Read Article
Adalimumab Gets FDA Orphan Drug Status for Use in Hidradenitis Suppurativa
The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).
Read Article